| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.092 | 0.004 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.095 | 0.004 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.14 | 0.005 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.099 | 0.005 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.094 | 0.005 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.14 | 0.006 |